EU Backs Down In Row Over AstraZeneca Vaccine Supplies
Company Offers 9 Million Extra Doses
Executive Summary
The European Commission has averted all-out conflict with AstraZeneca and the UK government, with good news from J&J and Pfizer/BioNTech easing supply concerns.
You may also be interested in...
CEOs Face Grilling On Vaccine Supply In EU
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Stung By COVID Critics, EU Looks To BARDA-Style Agency To Act Faster On Variants
The European Commission wants to learn from mistakes made in the COVID-19 crisis and to create an end-to-end system to co-ordinate funding, clinical research and manufacturing of vaccines.
Coronavirus Update: US FDA Panel To Review J&J’s Vaccine On 26 February
Johnson & Johnson's vaccine produced a significantly lower efficacy readout than the mRNA frontrunners, but its success in preventing severe disease with one dose will be a gamechanger, if approved.